var data={"title":"Amikacin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amikacin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5608?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amikacin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amikacin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Amikacin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708619\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Ototoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Neurotoxicity, manifested as vestibular and permanent bilateral auditory ototoxicity, can occur in patients with preexisting renal damage and in patients with normal renal function treated at higher doses and/or periods longer than those recommended. The risk of aminoglycoside-induced ototoxicity is greater in patients with renal damage. High frequency deafness usually occurs first and can be detected only by audiometric testing. Vertigo may occur and may be evidence of vestibular injury. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching, and convulsions. The risk of hearing loss due to aminoglycosides increases with the degree of exposure to either high peak or high trough serum concentrations. Patients developing cochlear damage may not have symptoms during therapy to warn them of developing eighth-nerve toxicity, and total or partial irreversible bilateral deafness may occur after the drug has been discontinued. Aminoglycoside-induced ototoxicity is usually irreversible. Patients treated with parenteral aminoglycosides should be under close clinical observation because of the potential ototoxicity associated with their use. Safety for treatment periods which are longer than 14 days has not been established. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nephrotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\"> Aminoglycosides are potentially nephrotoxic. The risk of nephrotoxicity is greater in patients with impaired renal function and in those who receive high doses or prolonged therapy. Patients treated with parenteral aminoglycosides should be under close clinical observation because of the potential nephrotoxicity associated with their use. Safety for treatment periods which are longer than 14 days has not been established.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neuromuscular blockade:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular blockade and respiratory paralysis have been reported following parenteral injection, topical instillation (as in orthopedic and abdominal irrigation or in local treatment of empyema), and following oral use of aminoglycosides. The possibility of these phenomena should be considered if aminoglycosides are administered by any route, especially in patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate-anticoagulated blood. If blockage occurs, calcium salts may reverse these phenomena, but mechanical respiratory assistance may be necessary.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Monitoring:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Renal and eighth-nerve function should be closely monitored especially in patients with known or suspected renal impairment at the onset of therapy and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Serum concentrations of amikacin should be monitored when feasible to assure adequate levels and to avoid potentially toxic levels and prolonged peak concentrations above 35 mcg/mL. Urine should be examined for decreased specific gravity, increased excretion of proteins, and the presence of cells or casts. Blood urea nitrogen, serum creatinine, or creatinine clearance should be measured periodically. Serial audiograms should be obtained where feasible in patients old enough to be tested, particularly high-risk patients. Evidence of ototoxicity (dizziness, vertigo, tinnitus, roaring in the ears, and hearing loss) or nephrotoxicity requires discontinuation of the drug or dosage adjustment.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Concurrent therapy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concurrent and/or sequential systemic, oral, or topical use of other neurotoxic or nephrotoxic products, particularly bacitracin, cisplatin, amphotericin B, cephaloridine, paromomycin, viomycin, polymyxin B, colistin, vancomycin, or other aminoglycosides should be avoided. Other factors that may increase risk of toxicity are advanced age and dehydration.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The concurrent use of amikacin with potent diuretics (ethacrynic acid, or furosemide) should be avoided because diuretics by themselves may cause ototoxicity. In addition, when administered intravenously, diuretics may enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132946\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Amikacin Sulfate Injection, USP;</li>\n      <li>Amikin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132990\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Aminoglycoside</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132949\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Individualization is critical because of the low therapeutic index</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>In underweight and nonobese patients, use of total body weight (TBW) instead of ideal body weight for determining the initial mg/kg/dose is widely accepted (Nicolau, 1995). Ideal body weight (IBW) also may be used to determine doses for patients who are neither underweight nor obese (Gilbert 2009).</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Initial and periodic peak and trough plasma drug levels should be determined, particularly in critically-ill patients with serious infections or in disease states known to significantly alter aminoglycoside pharmacokinetics (eg, cystic fibrosis, burns, or major surgery). Manufacturer recommends a maximum daily dose of 15 mg/kg/day (or 1.5 g/day in heavier patients). Higher doses may be warranted based on therapeutic drug monitoring or susceptibility information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV: 5 to 7.5 mg/kg/dose every 8 hours; <b>Note:</b> Some clinicians suggest a daily dose of 15 to 20 mg/kg/day for all patients with normal renal function. This dose is at least as efficacious with similar, if not less, toxicity than conventional dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intrathecal/intraventricular (off-label route): Meningitis (susceptible gram-negative organisms): 5 to 50 mg/day (Gilbert, 1986; Guardado 2008; IDSA 2004; Kasiakou 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis exacerbation (off-label use/route): Inhalation for nebulization:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Monotherapy:  500 mg twice daily (Le 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adjunctive therapy:  100 mg twice daily with concomitant IV amikacin and ceftazidime (Schaad 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endophthalmitis, bacterial (off-label use):</b> Intravitreal: 0.4 mg/0.1 mL NS in combination with vancomycin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis (susceptible gram-negative organisms):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 5 mg/kg every 8 hours (administered with another bactericidal drug) (IDSA 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intrathecal/intraventricular (off-label route): Usual dose: 30 mg/day (IDSA 2004); Range: 5 to 50 mg/day (with concurrent systemic antimicrobial therapy) (Gilbert, 1986; Guardado 2008; IDSA 2004; Kasiakou 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Mycobacterium avium </i></b>\n      <b> complex (MAC) (off-label use):</b> IV: Adjunct therapy (with macrolide, rifamycin, and ethambutol): 8 to 25 mg/kg 2 to 3 times weekly for first 2 to 3 months for severe disease (maximum single dose for age &gt;50 years: 500 mg) (Griffith 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Mycobacterium fortuitum, M. chelonae, or M. abscessus:</i></b> IV: 10 to 15 mg/kg daily for at least 2 weeks with high dose cefoxitin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, hospital-acquired (HAP) or ventilator-associated (VAP) (alternative therapy) (off-label dose): IV: </b>15 to 20 mg/kg/dose once every 24 hours for 7 days; may consider shorter or longer durations depending on rate of clinical improvement. When used as empiric therapy, use in combination with an agent active against <i>S. aureus</i> and an additional antipseudomonal agent. <b>Note:</b> Aminoglycosides are not recommended as monotherapy in patients with HAP or VAP due to <i>P. aeruginosa</i> (Kalil 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132971\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Amikacin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>General dosing, severe, susceptible infections:</b> Infants, Children, and Adolescents: IM, IV: 15 to 22.5 mg/kg/<b>day</b> divided every 8 hours <b>or</b> 15 to 20 mg/kg/<b>dose</b> every 24 hours (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dosage should be based on an estimate of ideal body weight. In morbidly obese children and adolescents, dosage requirement may best be estimated using a dosing weight of IBW + 0.4 (TBW - IBW). Initial dosing recommendation presented; dosage should be individualized based upon serum concentration monitoring. Initial and periodic plasma drug concentrations (eg, peak and trough with conventional dosing, post dose level at a prespecified time with extended-interval dosing) should be determined, particularly in critically ill patients with serious infections or in disease states known to significantly alter aminoglycoside pharmacokinetics (eg, cystic fibrosis, burns, or major surgery).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CNS infections (off-label dose):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Meningitis (Tunkel 2004):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: IV: 20 to 30 mg/kg/<b>day</b> divided every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: IV: 15 mg/kg/<b>day</b> divided every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">VP-shunt infection, ventriculitis: Limited data available: Intraventricular/intrathecal <b>(use a preservative free preparation)</b>: Infants, Children, and Adolescents: 5 to 50 mg/<b>day</b>; usual dose: 30 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis, pulmonary infection (systemic use) (off-label use):</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Traditional dosing: IV, IM: 10 mg/kg/dose every 8 hours (Wallace 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-interval dosing: IV: 30 mg/kg/dose every 24 hours (Flume 2009); <b>Note:</b> The CF Foundation recommends extended-interval dosing as preferred over traditional dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis, pulmonary infection</b> <b>(inhalational use; off-label use/route):</b> Inhalation for nebulization:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;14 years: Monotherapy: Refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;3 years and Adolescents: Adjunctive therapy: Refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment (off-label dose):</b> Children and Adolescents: IV: 15 mg/kg/<b>day </b>divided every 8 to 12 hours; use in combination with other antibiotics dependent upon organism and source of infection (ie, valve-type) (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated (off-label dose):</b> Infants, Children and Adolescents: IV: 15 to 22.5 mg/kg/day divided every 8 to 24 hours (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Mycobacterium, avium complex infection (MAC) (off-label use):</b> HIV-exposed/-positive:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: IV: 15 to 30 mg/kg/<b>day</b> divided every 12 to 24 hours as part of a multiple drug regimen; maximum daily dose: 1,500 mg/<b>day</b> (HHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: IV: 10 to 15 mg/kg/<b>day</b> every 24 hours as part of a multiple drug regimen (HHS [adult] 2015; HHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (CAPD):</b> Infants, Children, and Adolescents: Intraperitoneal: Continuous: Loading dose: 25 mg per liter of dialysate; maintenance dose: 12 mg per liter (Warady 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tuberculosis, drug-resistant (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents &le;14 years: IM, IV: 15 to 30 mg/kg/dose once daily as part of a multiple drug regimen; maximum daily dose: 1,000 mg/<b>day</b> (ATS/CDC/IDSA 2003; HHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;15 years, HIV-exposed/-positive: IM, IV: 15 mg/kg/dose once daily as part of a multiple drug regimen for the first 2 to 3 months; maximum daily dose: 1,000 mg/<b>day</b> (ATS/CDC/IDSA 2003;)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132950\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132951\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">Some patients may require larger or more frequent doses if serum levels document the need (ie, cystic fibrosis or febrile granulocytopenic patients). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Adults:</b> The following adjustments have been recommended: <b>Note: </b>Renally adjusted dose recommendations are based on a dose of 7.5 mg/kg every 12 hours (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GFR &gt;50 mL/minute: No dosage adjustment necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GFR 10 to 50 mL/minute: Administer every 24 to 72 hours based on serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GFR &lt;10 mL/minute: Administer every 48 to 72 hours based on serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (20%; variable; dependent on filter, duration, and type of HD): 5 to 7.5 mg/kg every 48 to 72 hours. Follow levels. Redose when pre-HD concentration &lt;10 mg/L; redose when post-HD concentration &lt;6 to 8 mg/L (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Peritoneal dialysis (PD) (Li 2010): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intermittent dosing: 2 mg/kg per exchange once daily; allow to dwell &ge;6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Continuous dosing  (all exchanges): Loading dose: 25 mg/L; maintenance dose: 12 mg/L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CVVH/CVVHD/CVVHDF: Loading dose of 10 mg/kg followed by maintenance dose of 7.5 mg/kg every 24 to 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> For severe gram-negative rod infections, target peak concentration of 15 to 30 mg/L; redose when concentration &lt;10 mg/L (Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Infants, Children, and Adolescents:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, the following adjustments have been recommended (Aronoff 2007): </p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Renally adjusted dose recommendations are based on doses of 5 to 7.5 mg/kg/dose every 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Administer every 12 to 18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Administer every 18 to 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer every 48 to 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intermittent hemodialysis: 5 mg/kg/dose; redose as indicated by serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Peritoneal dialysis (PD): 5 mg/kg/dose; redose as indicated by serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Continuous renal replacement therapy (CRRT): 7.5 mg/kg/dose every 12 hours, monitor serum concentrations</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671595\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20330478\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">In moderate obesity (TBW/IBW &ge;1.25) or greater (eg, morbid obesity [TBW/IBW &gt;2]), initial dosage requirement may be estimated using a dosing weight of IBW + 0.4 (TBW - IBW) (Traynor 1995).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132922\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg/2 mL (2 mL); 1 g/4 mL (4 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sulfate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg/2 mL (2 mL); 1 g/4 mL (4 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132905\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132927\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Administer IM injection in large muscle mass. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse over 30 to 60 minutes (children, adolescents, and adults) or over 1 to 2 hours (infants).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate  <i>in vitro</i>. This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy <i>in vivo</i>, particularly in the setting of profound renal impairment. However, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Intrathecal/Intraventricular (off-label route): Reserved solely for meningitis due to susceptible gram-negative organisms. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Inhalation (off-label route): Nebulization: Use with standard jet nebulizer connected to an air compressor or ultrasonic nebulizer; administer with mouthpiece or face mask (Le 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132926\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Serious infections:</b> Treatment of serious infections (eg, bone infections, respiratory tract infections, endocarditis, septicemia) due to gram-negative organisms, including <i>Pseudomonas</i>, <i>Escherichia coli</i>, <i>Proteus</i>, <i>Providencia</i>, <i>Klebsiella</i>, <i>Enterobacter</i>, <i>Serratia</i>, and <i>Acinetobacter</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475024\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cystic fibrosis exacerbation (aerosolized amikacin); Mycobacterium avium complex (MAC); Tuberculosis; Bacterial endophthalmitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132998\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amikacin may be confused with Amicar, anakinra </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amikin may be confused with Amicar, Kineret</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132913\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Neurotoxicity </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Nephrotoxicity </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Auditory ototoxicity, vestibular ototoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Arthralgia, drowsiness, drug fever, dyspnea, eosinophilia, headache, hypersensitivity reaction, hypotension, nausea, paresthesia, skin rash, tremor, vomiting, weakness </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132930\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to amikacin, other aminoglycosides, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132910\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Cross-sensitivity to other aminoglycosides may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nephrotoxicity:<b> [US Boxed Warning]: May cause nephrotoxicity;</b> usual risk factors include preexisting renal impairment, concomitant nephrotoxic medications, advanced age and dehydration. Discontinue treatment if signs of nephrotoxicity occur; renal damage is usually reversible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular blockade and respiratory paralysis:<b> [US Boxed Warning]: May cause neuromuscular blockade and respiratory paralysis; </b> especially when given soon after anesthesia or muscle relaxants.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: <b>[US Boxed Warning]: May cause neurotoxicity; </b>usual risk factors include preexisting renal impairment, concomitant neuro-/nephrotoxic medications, advanced age and dehydration. Ototoxicity is proportional to the amount of drug given and the duration of treatment. Tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage. Discontinue treatment if signs of ototoxicity occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hearing impairment: Use with caution in patients with preexisting vertigo, tinnitus, or hearing loss.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypocalcemia: Use with caution in patients with hypocalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis or parkinsonism. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with preexisting renal insufficiency; dosage modification required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxic and/or nephrotoxic drugs:<b> [US Boxed Warning]: Avoid concomitant or sequential use of other neurotoxic and/or nephrotoxic drugs (eg, bacitracin, cisplatin, amphotericin B, paromomycin, polymyxin B, colistin, vancomycin, other aminoglycosides).</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Potent diuretics: <b>[US Boxed Warning]: Avoid concomitant use with potent diuretics (eg, ethacrynic acid, furosemide) since diuretics themselves may cause ototoxicity and may enhance aminoglycoside toxicity.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sulfites: May contain sulfites which may cause allergic-type reactions (including anaphylaxis) as well as life-threatening or less severe asthmatic episodes in certain individuals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Surgical irrigation: Irreversible deafness, renal failure, and death due to neuromuscular blockade have been reported following use of aminoglycosides as surgical irrigation; rapid systemic absorption occurs with topical application (except to the urinary bladder).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298732\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132915\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8536&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Arbekacin: May enhance the nephrotoxic effect of Aminoglycosides. Arbekacin may enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ataluren: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, an increased risk of nephrotoxicity may occur with the concomitant use of ataluren and aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefazedone: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephradine: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distigmine: Aminoglycosides may diminish the therapeutic effect of Distigmine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mannitol (Systemic): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Aminoglycosides may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Aminoglycosides may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.<b> Exceptions: </b>Amoxicillin; Ampicillin; Bacampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Benzathine; Penicillin V Potassium.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Aminoglycosides may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132918\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5722003\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Adverse events were not observed in the initial animal reproduction studies. Amikacin crosses the placenta and produces detectable concentrations in the fetus. Aminoglycosides may cause fetal harm if administered to a pregnant woman. There are several reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy. Although serious side effects to the fetus/infant have not been reported following maternal use of all aminoglycosides, a potential for harm exists.  </p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of amikacin may be altered (Bernard 1977). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132933\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Amikacin is excreted into breast milk (trace amounts) (Matsuda 1984).  Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother. As a class, aminoglycosides are expected to be poorly distributed into breast milk, limiting systemic exposure to a nursing infant. In general, modification of bowel flora may occur with any antibiotic exposure (Chung 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132934\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132920\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Urinalysis, BUN, serum creatinine, appropriately timed peak and trough concentrations, vital signs, temperature, weight, I &amp; O, hearing parameters</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\"> Initial and periodic peak and trough plasma drug levels should be determined, particularly in critically-ill patients with serious infections or in disease states known to significantly alter aminoglycoside pharmacokinetics (eg, cystic fibrosis, burns, or major surgery). Aminoglycoside levels measured from blood taken from Silastic&reg; central catheters can sometimes give falsely high readings (draw levels from alternate lumen or peripheral stick, if possible).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Some penicillin derivatives may accelerate the degradation of aminoglycosides <i>in vitro</i>. This may be clinically-significant for certain penicillin (ticarcillin, piperacillin, carbenicillin) and aminoglycoside (gentamicin, tobramycin) combination therapy in patients with significant renal impairment. Close monitoring of aminoglycoside levels is warranted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132923\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;\">Traditional dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Therapeutic levels:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peak:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Life-threatening infections: 25 to 40 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serious infections: 20 to 25 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Urinary tract infections: 15 to 20 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Trough: &lt;8 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">The American Thoracic Society (ATS) recommends trough levels of &lt;4 to 5 mcg/mL for patients with hospital-acquired pneumonia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Toxic concentration: Peak: &gt;40 mcg/mL; Trough: &gt;10 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Timing of serum samples: Draw peak 30 minutes after completion of 30-minute infusion or at 1 hour following initiation of infusion or IM injection; draw trough within 30 minutes prior to next dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Extended-interval (once-daily) dosing: Obtain a random amikacin level between 6 and 14 hours after the start of the amikacin infusion. Refer to institution-specific nomogram/policies to determine appropriate dosing interval. If an amikacin-specific nomogram is not available, the amikacin level should be divided by 2 and the result evaluated using a gentamicin or tobramycin dosing nomogram. When therapy is continued for 5 days or more, monitor the amikacin level once or twice weekly (Bailey 1997; Nicolau 1995).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132909\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits protein synthesis in susceptible bacteria by binding to 30S ribosomal subunits</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132929\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Poorly absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 0.25 L/kg (Vozeh 1988); primarily into extracellular fluid (highly hydrophilic); poor penetration into the blood-brain barrier even when meninges are inflamed; V<sub>d</sub> is increased in neonates and patients with edema, ascites, fluid overload; V<sub>d</sub> is decreased in patients with dehydration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Relative diffusion of antimicrobial agents from blood into CSF: Good only with inflammation (exceeds usual MICs)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CSF:blood level ratio: Infants: Normal meninges: 10% to 20%; Inflamed meninges: up to 50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein-binding: 0% to 11%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination (renal function and age dependent):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: Low birth weight (1 to 3 days): 7 to 9 hours; Full-term &gt;7 days: 4 to 5 hours (Howard 1975)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: 1.6 to 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: 1.5 &plusmn; 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Normal renal function: ~2 hours; Anuria/end-stage renal disease: 17 to 150 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IM: 60 minutes; IV: Within 30 minutes following a 30-minute infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (94% to 98% unchanged)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322981\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Amikacin Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/4 mL (4 mL): $18.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/2 mL (2 mL): $9.30</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132935\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acemycin (TW);</li>\n      <li>Agnicin (MX);</li>\n      <li>Akacin (MX, TH);</li>\n      <li>Akamigis (VN);</li>\n      <li>Akicin (TH);</li>\n      <li>Akim (EC);</li>\n      <li>Alostil (ID);</li>\n      <li>Amibiotic (UA);</li>\n      <li>Amicacina (ES);</li>\n      <li>Amicare (PH);</li>\n      <li>Amicasil (IT);</li>\n      <li>Amicilon (BR);</li>\n      <li>Amicin (IN);</li>\n      <li>Amikabiot (PE);</li>\n      <li>Amikacin Fresenius (DE);</li>\n      <li>Amikacina (CL);</li>\n      <li>Amikacina Normon (PT);</li>\n      <li>Amikafur (MX);</li>\n      <li>Amikagram (PE);</li>\n      <li>Amikan (IT);</li>\n      <li>Amikaxing (CN);</li>\n      <li>Amikayect (MX);</li>\n      <li>Amikin (BD, BF, BJ, CH, CI, CO, CZ, EC, EE, EG, ET, GB, GH, GM, GN, HK, IE, JO, KE, KR, KW, LR, MA, ML, MR, MT, MU, MW, NE, NG, NZ, PE, PK, PL, QA, SA, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Amikin. (MX);</li>\n      <li>Amiklin (FR);</li>\n      <li>Amikozit (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, RO, RU, SA, SY, TR, YE);</li>\n      <li>Amiktam (KR);</li>\n      <li>Amiosin (ID);</li>\n      <li>Amitax (PH);</li>\n      <li>Amitsyl (UA);</li>\n      <li>Ampro (LK);</li>\n      <li>Amukin (BE, LU, NL);</li>\n      <li>Apalin (MY);</li>\n      <li>Biclin (MX, PT);</li>\n      <li>Biklin (AR, AT, DE, FI, SE, VE);</li>\n      <li>Biodacyna (LT);</li>\n      <li>Biokacin (MX, PY);</li>\n      <li>Biomikin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Briclin (UY);</li>\n      <li>Briklin (GR);</li>\n      <li>Chemacin (IT);</li>\n      <li>Cinamak (BD);</li>\n      <li>Cinmik (PH);</li>\n      <li>Eukacin (TW);</li>\n      <li>Flekselit (UA);</li>\n      <li>Gamikal (MX);</li>\n      <li>Glukamin (EC);</li>\n      <li>Glybotic (ID);</li>\n      <li>Indobact (PY);</li>\n      <li>Kacin (BD);</li>\n      <li>Kacinth-A (ZA);</li>\n      <li>Kamicin (ET);</li>\n      <li>Kamin (PH);</li>\n      <li>Kamina (PT);</li>\n      <li>Karmikin (MX);</li>\n      <li>Kormakin (PH);</li>\n      <li>Lanomycin (GR);</li>\n      <li>Likacin (AE, BH, CY, EG, HU, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SG, SY, VN, YE);</li>\n      <li>Likacin Gel (TH);</li>\n      <li>Lisobac (MX);</li>\n      <li>Lorikatsyn (UA);</li>\n      <li>Lukadin (IT);</li>\n      <li>Miacin (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Mikaciland (PY);</li>\n      <li>Mikacin (AE, BD, BH, KW, QA, SA);</li>\n      <li>Mikaject (ID);</li>\n      <li>Mikasin (ID);</li>\n      <li>Mikin (KR);</li>\n      <li>Nicin (LK);</li>\n      <li>Oprad (MX);</li>\n      <li>Orlobin (GR, MT);</li>\n      <li>Psudonil (BD);</li>\n      <li>Ramickin (KR);</li>\n      <li>Riklinak (AR);</li>\n      <li>Savox (TW);</li>\n      <li>Selaxa (GR);</li>\n      <li>Selemycin (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Sikacin (TW);</li>\n      <li>Simikan (ID);</li>\n      <li>Tybikin (TH);</li>\n      <li>Uzix (GR, MT);</li>\n      <li>Verdix (ID);</li>\n      <li>Vijomikin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Yectamid (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amikacin [prescribing information]. Eatontown, NJ: Heritage Pharmaceuticals; December 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Armstrong DK, Hodgman T, Visconti JA , et al, &ldquo;Hemodialysis of Amikacin in Critically Ill Patients,&rdquo; <i>Crit Care Med</i>, 1988, 16(5):517-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/3359790/pubmed\" target=\"_blank\" id=\"3359790\">3359790</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children,</i> 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey TC, Little JR, Littenberg B, Rechley RM, Dunagan WC. A meta-analysis of extended interval dosing versus multiple daily dosing of aminoglycosides. <i>Clin Infect Dis</i>. 1997;24(5):786-795.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/9142771/pubmed\" target=\"_blank\" id=\"9142771\">9142771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26373317\"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer LA and Blouin RA, &ldquo;Influence of Age on Amikacin Pharmacokinetics in Patients Without Renal Disease. Comparison With Gentamicin and Tobramycin,&rdquo; <i>Eur J Clin Pharmacol</i>, 1983, 24(5):639-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/6873143/pubmed\" target=\"_blank\" id=\"6873143\">6873143</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Begg EJ and Barclay ML, &ldquo;Aminoglycosides - 50 Years On,&rdquo; <i>Br J Clin Pharmacol</i>, 1995, 39(6):597-603.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/7654476/pubmed\" target=\"_blank\" id=\"7654476\">7654476</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bernard B, Abate M, Thielen PF, et al, &quot;Maternal-Fetal Pharmacological Activity of Amikacin,&quot; <i>J Infect Dis</i>, 1977, 135(6):925-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/864287/pubmed\" target=\"_blank\" id=\"864287\">864287</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America,&rdquo; 2003, <i>MMWR Recomm Rep</i>, 52(RR-11):3-5. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/12836625/pubmed\" target=\"_blank\" id=\"12836625\">12836625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow MS, Quintiliani R, and Nightingale CH, &quot;<i>In Vivo</i> Inactivation of Tobramycin by Ticarcillin. A Case Report,&quot; <i>JAMA</i>, 1982, 247(5):658-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/6798229/pubmed\" target=\"_blank\" id=\"6798229\">6798229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/12431134 /pubmed\" target=\"_blank\" id=\"12431134 \">12431134 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cunha BA, &ldquo;Aminoglycosides: Current Role in Antimicrobial Therapy,&rdquo; <i>Pharmacotherapy</i>, 1988, 8(6):334-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/3146747/pubmed\" target=\"_blank\" id=\"3146747\">3146747</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daly JS, Dodge RA, Glew RH, et al, &quot;Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages,&quot; <i>J Perinatol</i>, 1997, 17(1):42-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/9069064/pubmed\" target=\"_blank\" id=\"9069064\">9069064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013.  <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA). May 7, 2013. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell JA, Korth-Bradley J, Milisci M, et al, &quot;Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment,&quot; <i>J Clin Pharmacol</i>, 2001, 41:979-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/11549103/pubmed\" target=\"_blank\" id=\"11549103\">11549103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edson RS and Terrell CL, &ldquo;The Aminoglycosides,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(5):519-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/10319086/pubmed\" target=\"_blank\" id=\"10319086\">10319086</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farchione LA, &quot;Inactivation of Aminoglycosides by Penicillins,&quot; <i>J Antimicrob Chemother</i>, 1982, 8(Suppl A):27-36.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flandrois JP, Bouletreau P, Auboyer R, et al, &ldquo;Accidental Amikacin Overdose in Man: Emergency Therapy by Extrarenal Dialysis,&rdquo; <i>Infection</i>, 1979, 7:190-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/511337/pubmed\" target=\"_blank\" id=\"511337\">511337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19729669\"></a>Flume PA, Mogayzel PJ Jr, Robinson KA, et al; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. <i>Am J Respir Crit Care Med.</i> 2009;180(9):802-808.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/19729669/pubmed\" target=\"_blank\" id=\"19729669\">19729669</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuchs PC, Stickel S, Anderson PH, et al, &quot;<i>In Vitro</i> Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations,&quot; <i>Antimicrob Agents Chemother</i>, 1991, 35(1):182-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/2014975/pubmed\" target=\"_blank\" id=\"2014975\">2014975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilbert DN, &ldquo;Once-Daily Aminoglycoside Therapy,&rdquo; <i>Antimicrob Agents Chemother</i>, 1991, 35(3):399-405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/2039189/pubmed\" target=\"_blank\" id=\"2039189\">2039189</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilbert VE, Beals JD, Natelson ST, et al, &ldquo;Treatment of Cerebrospinal Fluid Leaks and Gram-negative Bacillary Meningitis With Large Doses of Intrathecal Amikacin and Systemic Antibiotics,&rdquo; <i>Neurosurgery</i>, 1986, 18(4):402-06.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/3754626/pubmed\" target=\"_blank\" id=\"3754626\">3754626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilbert DN and Leggett JE, &ldquo;Aminoglycosides,&rdquo; <i>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases,</i> 7th ed, Chapter 26, Mandell GL, Bennett JE, and Dolin R, eds, Philadelphia, PA: Churchill Linvingstone Elsevier, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Green FJ, Lavelle KJ, and Aronoff GR, &ldquo;Management of Amikacin Overdose,&rdquo; <i>Am J Kidney Dis</i>, 1981, 1:110-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/7332003/pubmed\" target=\"_blank\" id=\"7332003\">7332003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griffith DE, Aksamit T, Brown-Elliott BA, et al, &ldquo;An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases,&rdquo; <i>Am J Respir Crit Care Med</i>, 2007, 175(4):367-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/17277290/pubmed\" target=\"_blank\" id=\"17277290\">17277290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guardado AR, Blanco A, Asensi V, et al, &ldquo;Multidrug-Resistant <i>Acinetobacter</i> Meningitis in Neurosurgical Patients With Intraventricular Catheters: Assessment of Different Treatments,&rdquo; <i>J Antimicrob Chemother</i>, 2008, 61(4):908-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/18281693/pubmed\" target=\"_blank\" id=\"18281693\">18281693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halstenson CE, Wong MO, Herman CS, et al, &quot;Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease,&quot; <i>Antimicrob Agents Chemother</i>, 1992, 36(9):1832-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/1416875/pubmed\" target=\"_blank\" id=\"1416875\">1416875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hitt CM, Patel KB, Nicolau DP, et al, &quot;Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily,&quot; <i>Am J Health Syst Pharm</i>, 1997, 54(23):2704-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/9408514/pubmed\" target=\"_blank\" id=\"9408514\">9408514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ho PW, Pien FD, and Kominami N, &ldquo;Massive Amikacin Overdose,&rdquo; <i>Ann Intern Med</i>, 1979, 91:227-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/464467/pubmed\" target=\"_blank\" id=\"464467\">464467</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howard JB, McCracken GH. &quot;Pharmacological evaluation of Amikacin in Neonates&quot;. <i>Antimicrob Agents Chemother</i>. 1975; 8(1):86-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/1164009/pubmed\" target=\"_blank\" id=\"1164009\">1164009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013.  <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA). May 7, 2013. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iseman MD, &ldquo;Treatment of Multidrug-Resistant Tuberculosis,&rdquo; <i>N Engl J Med</i>, 1993, 329(11):784-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/8350889/pubmed\" target=\"_blank\" id=\"8350889\">8350889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciw353.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/27418577/pubmed\" target=\"_blank\" id=\"27418577\">27418577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kasiakou SK, Rafailidis PI, Liaropoulos K, et al, &ldquo;Cure of Post-Traumatic Recurrent Multiresistant Gram-Negative  Rod Meningitis With Intraventricular Colistin,&rdquo; <i>J Infect</i>, 2005, 50(4):348-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/15845435/pubmed\" target=\"_blank\" id=\"15845435\">15845435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kenyon CF, Knoppert DC, Lee SK, et al, &ldquo;Amikacin Pharmacokinetics and Suggested Dosage Modifications for the Preterm Infant,&rdquo; <i>Antimicrob Agents Chemother</i>, 1990, 34(2):265-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/2327775/pubmed\" target=\"_blank\" id=\"2327775\">2327775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Konishi H, Goto M, Nakamoto Y, et al, &quot;Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin,&quot; <i>Antimicrob Agents Chemother</i>, 1983, 23(5):653-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/6223576/pubmed\" target=\"_blank\" id=\"6223576\">6223576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lau A, Lee M, Flascha S, et al, &quot;Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients With Normal Renal Function,&quot; <i>Antimicrob Agents Chemother</i>, 1983, 24(4):533-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/6651279/pubmed\" target=\"_blank\" id=\"6651279\">6651279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Le J, Ashley ED, Neuhauser MM, et al. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists.  <i>Pharmacotherapy</i>. 2010;30(6):562-584.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/20500046/pubmed\" target=\"_blank\" id=\"20500046\">20500046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li PKT, Szeto CC, Piraino B, et al. Peritoneal Dialysis-Related Infections Recommendations: 2010 Update. Peritoneal Dialysis International. 2010; 30: 393-423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/20628102 /pubmed\" target=\"_blank\" id=\"20628102 \">20628102 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lortholary O, Tod M, Cohen Y, et al, &ldquo;Aminoglycosides,&rdquo; <i>Med Clin North Am</i>, 1995, 79(4):761-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/7791422/pubmed\" target=\"_blank\" id=\"7791422\">7791422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matsuda S, &quot;Transfer of Antibiotics Into Maternal Milk,&quot; <i>Biol Res Pregnancy Perinatol</i>, 1984, 5(2):57-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/6743732/pubmed\" target=\"_blank\" id=\"6743732\">6743732</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCormack JP and Jewesson PJ, &ldquo;A Critical Re-evaluation of the &ldquo;Therapeutic Range&rdquo; of Aminoglycosides,&rdquo; <i>Clin Infect Dis</i>, 1992, 14(1):320-39</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicolau DP, Freeman CD, Belliveau PP, et al, &ldquo;Experience With a Once-Daily Aminoglycoside Program Administered to 2184 Adult Patients,&rdquo; <i>Antimicrob Agents Chemother</i>, 1995, 39(3):650-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/7793867/pubmed\" target=\"_blank\" id=\"7793867\">7793867</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Preston SL and Briceland LL, &ldquo;Single Daily Dosing of Aminoglycosides,&rdquo; <i>Pharmacotherapy</i>, 1995, 15(3):297-316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/7667165/pubmed\" target=\"_blank\" id=\"7667165\">7667165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Public Health Service Task Force on Prophylaxis and Therapy for <i>Mycobacterium avium</i> Complex, &ldquo;Recommendations on Prophylaxis and Therapy for Disseminated <i>Mycobacterium avium</i> Complex Disease in Patients Infected With the Human Immunodeficiency Virus,&rdquo; <i>N Engl J Med</i>, 1993, 329(12):898-904.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/8395019/pubmed\" target=\"_blank\" id=\"8395019\">8395019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Results of the Endophthalmitis Vitrectomy Study. A Randomized Trial of Immediate Vitrectomy and of Intravenous Antibiotics for the Treatment of Postoperative Bacterial Endophthalmitis. Endophthalmitis Vitrectomy Study Group,&rdquo; <i>Arch Ophthalmol</i>, 1995, 113(12):1479-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/7487614/pubmed\" target=\"_blank\" id=\"7487614\">7487614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roth DB and Flynn HW Jr, &ldquo;Antibiotic Selection in the Treatment of Endophthalmitis: The Significance of Drug Combinations and Synergy,&rdquo; <i>Surv Ophthalmol</i>, 1997, 41(5):395-401.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/9163836/pubmed\" target=\"_blank\" id=\"9163836\">9163836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russoe ME and Atkins-Thor E, &quot;Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate,&quot; <i>Clin Nephrol</i>, 1981, 15(4):175-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/7237864/pubmed\" target=\"_blank\" id=\"7237864\">7237864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3309236\"></a>Schaad UB, Wedgwood-Krucko J, Suter S, Kraemer R. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. <i>J Pediatr</i>. 1987;111(4):599-605.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/3309236 /pubmed\" target=\"_blank\" id=\"3309236 \">3309236 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20034345\"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2010;50(2):133-164.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7667049\"></a>Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1995, 14(6):455-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/7667049/pubmed\" target=\"_blank\" id=\"7667049\">7667049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6462107\"></a>Thompson MIB, Russo ME, Saxon BJ, et al, &quot;Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease,&quot; <i>Antimicrob Agents Chemother</i>, 1982, 21(2):268-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/6462107/pubmed\" target=\"_blank\" id=\"6462107\">6462107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Traynor AM, Nafziger AN, and Bertino JS Jr, &ldquo;Aminoglycoside Dosing Weight Correction Factors for Patients of Various Body Sizes,&rdquo; <i>Antimicrob Agents Chemother</i>, 1995, 39(2):545-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/7726530/pubmed\" target=\"_blank\" id=\"7726530\">7726530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van der Auwera P, &ldquo;Pharmacokinetic Evaluation of Single Daily Dose Amikacin,&rdquo; <i>J Antimicrob Chemother</i>, 1991, 27(Suppl C):63-71.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanhaeverbeek M, Siska G, Douchamps J, et al, &ldquo;Comparison of the Efficacy and Safety of Amikacin Once or Twice-a-Day in the Treatment of Severe Gram-Negative Infections in the Elderly,&rdquo; <i>Int J Clin Pharmacol Ther Toxicol</i>, 1993, 31(3):153-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/8468114/pubmed\" target=\"_blank\" id=\"8468114\">8468114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viollier AF, Standiford HC, Drusano GL, et al, &quot;Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin and Piperacillin, With and Without Gentamicin,&quot; <i>J Antimicrob Chemother</i>, 1985, 15(5):597-606.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/4008387/pubmed\" target=\"_blank\" id=\"4008387\">4008387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vogelstein B, Kowarski A, and Lietman PS, &ldquo;The Pharmacokinetics of Amikacin in Children,&rdquo; <i>J Pediatr</i>, 1977, 91(2):333-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/874697/pubmed\" target=\"_blank\" id=\"874697\">874697</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vozeh S, Schmidlin O, and Taeschner W, &ldquo;Pharmacokinetic Drug Data,&rdquo; <i>Clin Pharmacokinetics</i>, 1988, 15(4):254-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/3191648/pubmed\" target=\"_blank\" id=\"3191648\">3191648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8306566\"></a>Wallace CS, Hall M, Kuhn RJ. Pharmacologic management of cystic fibrosis. <i>Clin Pharm</i>. 1993;12(9):657-674.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/8306566/pubmed\" target=\"_blank\" id=\"8306566\">8306566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walterspiel JN, Feldman S, Van R, et al, &quot;Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin,&quot;  <i>Antimicrob Agents Chemother</i>, 1991, 35(9):1875-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/1952861/pubmed\" target=\"_blank\" id=\"1952861\">1952861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22851742\"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int. </i>2012;(32)(suppl 2):S32-S86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo; Circulation, 2007, 115. Available at http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v1; last accessed July 26, 2007.17446442</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yasuhara H, Kobayashi S, Sakamoto K, et al, &ldquo;Pharmacokinetics of Amikacin and Cephalothin in Bedridden Elderly Patients,&rdquo; <i>J Clin Pharmacol</i>, 1982, 22(8-9):403-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-drug-information/abstract-text/7130429/pubmed\" target=\"_blank\" id=\"7130429\">7130429</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8536 Version 168.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708619\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F132946\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F132990\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F132949\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F132971\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F132950\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F132951\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671595\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20330478\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F132922\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F132905\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F132927\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F132926\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475024\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F132998\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F132913\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F132930\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F132910\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298732\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F132915\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F132918\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5722003\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F132933\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F132934\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F132920\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F132923\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F132909\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F132929\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322981\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F132935\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8536|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amikacin-patient-drug-information\" class=\"drug drug_patient\">Amikacin: Patient drug information</a></li><li><a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">Amikacin: Pediatric drug information</a></li></ul></div></div>","javascript":null}